OMERS ADMINISTRATION Corp Purchases Shares of 1,000,000 Drugs Made In America Acquisition II Corp. $DMII

OMERS ADMINISTRATION Corp purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,000,000 shares of the company’s stock, valued at approximately $9,900,000.

Several other institutional investors and hedge funds also recently bought and sold shares of DMII. Glazer Capital LLC purchased a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $23,264,000. First Trust Capital Management L.P. purchased a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $20,474,000. Hudson Bay Capital Management LP purchased a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $19,493,000. Wolverine Asset Management LLC purchased a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $10,521,000. Finally, Picton Mahoney Asset Management purchased a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $8,662,000.

Drugs Made In America Acquisition II Trading Up 0.0%

Shares of DMII stock opened at $10.09 on Tuesday. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.09. The stock has a 50-day moving average price of $10.03.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DMII. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.